Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Glasdegib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEINO 1602; GEINOGLAS
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.